We further explored the specific mechanism of lipid metabolism reprogramming promoting the progression of gastric cancer, and explored the relationship between lipid metabolism reprogramming and immune cell infiltration; Finally, we identified ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 (ST6GALNAC3) as a potential therapeutic target related to lipid metabolism, which will contribute to the immunotherapy of gastric cancer. Here, ST6GALNAC3 is linked to gastric cancer.